Maxim Group Thinks Daré Bioscience Inc’s Stock is Going to Recover


Maxim Group analyst Caroline Palomeque maintained a Buy rating on Daré Bioscience Inc (NASDAQ: DARE) today and set a price target of $3. The company’s shares opened today at $0.95, close to its 52-week low of $0.74.

Palomeque noted:

“Daré will present at the Partnership Opportunities in Drug Delivery (PODD) meeting in Boston, MA. The presentation is entitled “Optimizing Drug Delivery Through Novel Intra-Vaginal Ring (IVR) Technology” and will take place on Wednesday, October 17 during the Track 2B sessions.”

According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -8.2% and a 28.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.

Currently, the analyst consensus on Daré Bioscience Inc is a Moderate Buy with an average price target of $3.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.59 and a one-year low of $0.74. Currently, Daré Bioscience Inc has an average volume of 214.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Daré Bioscience, Inc. operates as a healthcare company. It engages in the development and commercialization of pharmaceutical products in women’s reproductive health. Its products inclide Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in La Jolla, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts